II. Epidemiology
- Uncommon type of Prostatitis, accounting for only 10% of cases
- Peak onset age 20-40 years old, and over age 70 years old
III. Pathophysiology: Mechanisms
- Ascending infection from infected Urethra or intraprostatic reflux (most cases)
- Bacterial Prostatitis and Pyelonephritis share the same Bladder source of infection
- Instrumentation (transrectal Prostate biopsy, Urinary Catheterization, cystoscopy)
- Direct or lymphatic spread from Rectum
- Hematogenous spread (Sepsis)
IV. Causes: Organisms
- Aerobic Gram Negative Rods (Enterobacteriaceae, most common)
-
Gram Positive Bacteria
- Enterococcus (common)
- Streptococcus faecalis (uncommon)
- Staphylococcus aureus (uncommon)
- After instrumentation or in hospitalized patients (up to 2% of cases)
- Pseudomonas
- Resistant organisms (ESBL e coli and Fluoroquinolone resistant)
- Sexually Transmitted Infection (typically age <35 years old)
-
Immunocompromised patients
- Salmonella
- Candida
- Cryptococcus
- Other uncommon organisms
- Tuberculous Prostatitis (Tuberculosis)
- Parasitic Prostatitis (e.g. Trichomonas vaginalis)
- Mycotic Prostatitis (Fungal organisms - Aspergillus, Candida, Cryptococcus, Histoplasma)
- Burkholderia pseudomallei
V. Risk Factors
- Benign Prostatic Hyperplasia
- Other genitourinary infection
- Urinary tract manipulation or instrumentation
- Urinary Catheterization or Indwelling Urethral catheter
- Condom Catheter Drainage
- Transrectal Prostate biopsy
- Transurethral surgery
- Infected sexual contact, STD History or high risk behavior
- Immunocompromised patients (e.g. HIV or AIDS, Diabetes Mellitus)
- Anatomic abnormalities
VI. Symptoms (sudden onset)
- Systemic symptoms
- Fever and chills
- Malaise
- Joint Pain (Arthralgia)
- Muscle pain (myalgia)
- Nausea or Vomiting
- Referred pain
- Low Back Pain
- Perineal pain or Rectal Pain
- Suprapubic Pain
- Irritative urinary symptoms
- Dysuria
- Urinary Frequency
- Urinary urgency
- Obstructive urinary symptoms
- Other
- Painful ejaculation
- Hematospermia
- Difficulty stooling (Dyschezia)
VII. Signs
- Ill, toxic appearing patient
- Abdominal exam
- Suprapubic tenderness if obstruction
- Genitourinary exam
- Examine the Scrotum and penis to exclude other causes (e.g. Epididymitis)
-
Digital Rectal Exam
- Avoid vigorous exam or Prostatic Massage (risk of bacteremia)
- Gentle exam is safe, and helps to identify source of infection
-
Prostate is warm, boggy, tender on palpation
- Prostate is tender out of proportion to what would be expected
- Prostate palpation may reproduce Prostatitis symptoms of urgency and pressure
- Normal Prostate exam makes Acute Prostatitis diagnosis much less likely
- Avoid vigorous exam or Prostatic Massage (risk of bacteremia)
VIII. Differential Diagnosis
- See Prostatitis
- Epididymitis (and Orchitis)
- Urethritis (Chlamydia, Gonorrhea)
- Urinary tract cancer
- Ureterolithiasis (including infected Ureteral Stone)
-
Acute Pyelonephritis
- Flank Pain seen in Pyelonephritis is typically absent in Acute Prostatitis
-
Urinary Tract Infection
- Uncommon in males unless Bladder outlet obstruction (e.g. BPH, neurologic disorder)
IX. Labs: Standard
- Urinalysis
- Urine Culture (negative in 35% of acute prostatis cases)
- STD Screening (if risk factors or in men under age 35 years old)
X. Labs: Severe cases
- Indications
- Indications for hospitalization (see below)
- Fever >101
- SIRS Criteria for Sepsis or increased serum Lactic Acid
- Hematogenous source of infection suspected
- Tests
- Complete Blood Count with differential (>18k in severe cases)
- Basic metabolic panel (BUN >19 in severe cases)
- Lactic Acid
- Blood Cultures x2
- Bacteremia present in 20% of inpatient cases
- Labs to avoid
- Avoid CRP or ESR (unlikely to direct care)
- Avoid PSA
- Expect PSA elevation for 2 months after acute infection
XI. Imaging
-
Bedside Ultrasound
- Evaluate for post-void residual Urine Volume (Urinary Retention)
- Other imaging for prostatic abscess (indicated in severe, refractory cases or fever >36 hours)
- Transrectal Ultrasound
- CT Pelvis
- MRI Pelvis
XII. Management: Indications for Hospitalization (<16% of Acute Prostatitis cases)
- Signs of bacteremia or Sepsis (fever>100.4, rigors)
- Urinary Retention
- Failed outpatient management (e.g. need for ParenteralAntibiotics)
- Significant Dehydration and inability to take oral fluids
- Post-instrumentation (e.g. status post transurethral catheterization)
- Older age (>65 years old) is associated with worse outcomes (but no formal age criteria for admission)
XIII. Management: Outpatient
- See Prostatitis General Measures
- Indicated for mild to moderate illness not meeting inpatient criteria above
- For mild Acute Prostatitis, 10 day Antibiotic course is sufficient
- Consider treatment of Gonorrhea and Chlamydia (esp. age <35 years old)
- Obtain baseline labs to include a dirty urine for Gonorrhea PCR and Chlamydia PCR
- Gonorrhea management
- Ceftriaxone 500 mg IM/IV for 1 dose (1 gram IM/IV if weight > 150 kg, dose increased in 2020) OR
- Gentamicin 240 mg IM and Azithromycin 2 g orally for one dose OR
- Cefixime 800 mg orally once is an alternative but NOT recommended due to Antibiotic Resistance
- Chlamydia management
- Doxycycline 100 mg twice daily for 7 days (preferred as of 2020) OR
- Azithromycin 1 g orally for 1 dose
- References
- Standard Antibiotic protocol (esp. age >35 years old, depending on local Antibiotic Resistance)
- May also use Antibiotics as listed under Chronic Prostatitis
- Longer courses may be required in more severe cases (up to 6 weeks)
- First-line medications
- Ciprofloxacin (Cipro) 500 mg orally twice daily for 10-14 days
- Levofloxacin (Levaquin) 500-750 mg orally daily for 10-14 days
- Alternative medications (Consider as first-line given risks of Fluoroquinolones)
- Trimethoprim Sulfamethoxazole (Septra, Bactrim) DS one orally twice daily for 10-14 days
-
AIDS Considerations
- Consider Cryptococcus neoformans as causative organism
- Other measures
- Consider Tamsulosin (Flomax) if obstructive symptoms (e.g. decreased urinary stream, double voiding)
XIV. Management: Inpatient
- Precautions
- Avoid Foley Catheter or Prostate massage (may place suprapubic drain as needed)
- Indicated if inpatient criteria met (see above)
- Step 0: Obtain labs
- Includes Urine Culture in all patients prior to Antibiotics (and consider Blood Culture)
- Step 1a: Antibiotics for non-seriously ill patients and no Antibiotic Resistance risk factors
- First-line: Fluoroquinolone (choose one)
- Ciprofloxacin 400 mg IV every 12 hours
- Levofloxacin 500-750 mg IV every 24 hours
- Alternative
- Piperacillin/tazobactam (Zosyn) 3.375 g IV every 6 hours OR
- Ceftriaxone 1-2 g IV every 24 hours AND Levofloxacin 500-750 mg IV every 24 hours
- First-line: Fluoroquinolone (choose one)
- Step 1b: Antibiotics for seriously ill patients but no Antibiotic Resistance risk factors
- First-line (dual coverage)
- Antibiotic 1: Aminoglycoside (choose one)
- Gentamicin 7 mg/kg every 24 hours (peak 16-24 mcg/ml, trough <1 mcg/ml)
- Amikacin 15 mg/kg IV every 24 hours (peak 56-64 mcg/ml, trough <1 mcg/ml)
- Antibiotic 2 (choose one)
- Piperacillin/tazobactam (Zosyn) 3.375 g IV every 6 hours OR
- Cefotaxime (Claforan) 2 g IV every 4 hours OR
- Ceftazidime (Fortaz) 2 g IV every 8 hours
- Antibiotic 1: Aminoglycoside (choose one)
- Alternative
- Fluoroquinolone (Ciprofloxacin or Levofloxacin) AND Aminoglycoside (Gentamicin or Amikacin) OR
- Ertapenem (Invanz) 1 g IV every 24 hours OR
- Imipenem/cilastin (Primaxin) 500 mg IV every 6 hours OR
- Meropenem (Merrem) 500 mg IV every 8 hours
- First-line (dual coverage)
- Step 1c: Antibiotics for resistance risks factors
- Transrectal instrumentation (Fluoroquinolone resistance and ESBL e coli risk)
- First-line (dual coverage)
- Piperacillin/tazobactam (Zosyn) 3.375 g IV every 6 hours AND
- Aminoglycoside (Gentamicin or Amikacin)
- Alternative
- First-line (dual coverage)
- Transurethral instrumentation (Pseudomonas risk)
- First-line
- Piperacillin/tazobactam (Zosyn) 3.375 g IV every 6 hours OR
- Ceftazidime (Fortaz) 2 g IV every 8 hours OR
- Cefepime 2 g IV every 12 hours
- Alternative
- Fluoroquinolone (Ciprofloxacin or Levofloxacin) OR
- Imipenem/cilastin (Primaxin) 500 mg IV every 6 hours
- Meropenem (Merrem) 500 mg IV every 8 hours
- First-line
- Fluoroquinolone exposure (Fluoroquinolone resistance suspected)
- First-line
- Piperacillin/tazobactam (Zosyn) 3.375 g IV every 6 hours OR
- Ceftazidime (Fortaz) 2 g IV every 8 hours OR
- Cefepime 2 g IV every 12 hours
- Alternative
- Ceftriaxone 1-2 g IV every 24 hours OR
- Ertapenem (Invanz) 1 g IV every 24 hours
- First-line
- Transrectal instrumentation (Fluoroquinolone resistance and ESBL e coli risk)
- Step 2: Lack of improvement or persistent fever
- Obtain Prostate imaging typically with CT Pelvis
- Other imaging options include transrectal Ultrasound or MRI Pelvis
- Imaging demonstrates Prostate abscess
- Urology consult for drainage
- Imaging negative
- Adjust Antibiotics based on Urine Culture results
- Obtain Prostate imaging typically with CT Pelvis
- Step 3: When affebrile
- Switch to oral Antibiotics as described above
- Antibiotics may need to be extended for a total of 2-4 weeks
XV. Complications
-
Prostate abscess (3 to 6% of cases)
- Identified on CT Pelvis or transrectal Ultrasound
- Requires surgical drainage and prolonged Antibiotic course
- Consider CT imaging in patients at higher risk of abscess
- Prolonged catheterization
- Recent instrumentation (Prostate biopsy, cystoscopy)
- Immunocompromised
- Ongoing fever >48 hours despite Antibiotics
- Ill, hospitalized patients
- Infection relapse despite adequate Antibiotic course
- Chronic Prostatitis >3 months (10% of cases)
- Recurrent Acute Prostatitis (13% of cases)
- Pyelonephritis
- Epididymitis
- Sepsis
- Acute urinary obstruction (10% cases)
XVI. Prevention
- Avoid Urethral Catheterization or transrectal biopsy if possible
- Prophylactic Antibiotics prior to transrectal biopsy (e.g. cipro 500 mg taken 12 hours before procedure)
XVII. References
- Cooner (1994) Prostate Disease, AAFP, p. 9-15
- (2018) Sanford Guide, IOS app, accessed 10/16/2019
- Krieger (Summer, 1998) Prostatitis, Patient Care Suppl.
- Spangler, Weinstock and Carmack in Herbert (2016) EM:Rap 16(11): 15-6
- Coker (2016) Am Fam Physician 93(2): 114-20 [PubMed]
- Holt (2016) Am Fam Physician 93(4):290-6 [PubMed]
- Lam (2024) Am Fam Physician 110(1): 45-51 [PubMed]
- Nickel (2005) Urology 66(1): 2-8 [PubMed]
- Pontari (2007) J Urol 177(6): 2050-7 [PubMed]
- Schwager (1991) Am Fam Physician, 44(6): 2137-41 [PubMed]
- Sharp (2010) Am Fam Physician 82(4): 397-406 [PubMed]